@conference{50085a6b66f44a34979a1bcbe4214f55,
title = "Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.",
author = "Isabel Arrillaga and Sylvia Kurz and Ashley Sumrall and Butowski, \{Nicholas A.\} and Harrison, \{Rebecca A.\} and \{De Groot\}, \{John Frederick\} and Shonka, \{Nicole A.\} and Lieberman, \{Frank S.\} and Yazmin Odia and Rohinton Tarapore and Krystal Merdinger and Allen, \{Joshua E.\} and Wolfgang Oster and Mehta, \{Minesh P.\} and Cloughesy, \{Timothy Francis\} and Chi, \{Andrew S.\} and Lassman, \{Andrew B.\} and Tracy Batchelor and Wen, \{Patrick Y.\}",
note = "3005 Background: H3 K27M-mutant glioma is associated with a poor prognosis and there is no effective therapy following radiation. We report the clinical experience with single agent ONC201, the first small molecule DRD2 antagonist in oncology, in adults with recurrent H3 K27M-mutant glioma.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2019",
month = may,
day = "20",
doi = "10.1200/jco.2019.37.15\_suppl.3005",
language = "American English",
}